On March 15, 2023 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence ("AI") and machine learning ("ML") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that the Company will present at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Lantern Pharma, MAR 15, 2023, View Source [SID1234628831]). Details on the AACR (Free AACR Whitepaper) presentation are provided below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
AACR Annual Meeting in Orlando, FL from April 14th-19th, 2023
Poster Title: LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers
Presentation Date and Time: Wednesday, April 19, 2023 from 9:00 a.m. – 12:30 p.m. ET
Abstract Link: View Source!/10828/presentation/6762
Registration: View Source
The AACR (Free AACR Whitepaper) presentation will focus on Lantern’s drug candidate LP-184 and its unique anti-cancer mechanism of action known as synthetic lethality. In oncology drug development, synthetic lethality has become a highly desired capability for small molecules as it promotes the selective anti-tumor toxicity of cancer cells, while reducing potential side effects to normal cells. This mechanism of action can exploit vulnerabilities in cancer cells, known as DNA damage repair deficiencies, which are common in 25-30% of solid tumors. Using synthetic lethality, Lantern’s drug candidate LP-184 has demonstrated nanomolar potency across a comprehensive number of in vitro and in vivo preclinical models in solid tumors as well as in adult and pediatric central nervous system cancers. Based on its synthetic lethality mechanism of action and strong preclinical results, Lantern is targeting advancing LP-184 to a first-in-human Phase 1 clinical trial in mid-2023.
Lantern will also be hosting a key opinion leader webinar on synthetic lethality on Tuesday, March 21, 2023 at 12:00 p.m. ET, featuring a leading expert in synthetic lethality, Zoltan Szallasi, M.D. Register for the webinar here.